Experienced in Primitive Neuroectodermal Tumor (PNET)

Dr. Anju Vasudevan

Oncology | Hematology Oncology | Hematology
Ocala Oncology Center Pl
13940 Us Hwy 441 N, Suite 203, 
Lady Lake, FL 
Accepting New Patients
Experienced in Primitive Neuroectodermal Tumor (PNET)
Ocala Oncology Center Pl
13940 Us Hwy 441 N, Suite 203, 
Lady Lake, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anju Vasudevan is an Oncologist and a Hematologist Oncology provider in Lady Lake, Florida. Dr. Vasudevan is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Iron Deficiency Anemia, Breast Cancer, Paget Disease of the Breast, Lung Cancer, and Bone Marrow Aspiration. Dr. Vasudevan is currently accepting new patients.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
Marion Communtiy Hospital
Adventhealth Ocala
Languages Spoken
English
Hindi
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

OCALA ONCOLOGY CENTER PL
13940 Us Hwy 441 N, Suite 203, Lady Lake, FL 32159
Other Locations
OCALA ONCOLOGY CENTER PL
9401 Sw State Rd, 200 Suite 702, Ocala, FL 34481
OCALA ONCOLOGY CENTER PL
3130 Sw 32nd Ave, Ocala, FL 34474

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 4 Less Clinical Trials

21 Total Publications

Higher sodium in older individuals or after stroke/reperfusion, but not in migraine or Alzheimer's disease - a study in different preclinical models.
Higher sodium in older individuals or after stroke/reperfusion, but not in migraine or Alzheimer's disease - a study in different preclinical models.
Journal: Scientific reports
Published: May 31, 2024
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Frederic J. Kaye
Hematology Oncology | Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Frederic J. Kaye
Hematology Oncology | Oncology
1600 Sw Archer Rd, 
Gainesville, FL 
 (58.4 miles away)
352-273-7760
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Frederic Kaye is a Hematologist Oncology specialist and an Oncologist in Gainesville, Florida. Dr. Kaye is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Lung Adenocarcinoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Kaye is currently accepting new patients.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Ashley Ghiaseddin
Neurology | Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Ashley Ghiaseddin
Neurology | Oncology

Florida Clinical Practice Association Inc

2001 Sw 13th St, 
Gainesville, FL 
 (57.9 miles away)
352-265-8990
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ashley Ghiaseddin is a Neurologist and an Oncologist in Gainesville, Florida. Dr. Ghiaseddin is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Praveen G. Ranganath
Oncology | Hematology Oncology | Hematology
Advanced in Primitive Neuroectodermal Tumor (PNET)
Dr. Praveen G. Ranganath
Oncology | Hematology Oncology | Hematology

Orlando Health Medical Group Inc

7472 Docs Grove Cir, 
Orlando, FL 
 (40.7 miles away)
407-896-1100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Praveen Ranganath is an Oncologist and a Hematologist Oncology provider in Orlando, Florida. Dr. Ranganath is rated as an Advanced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Ranganath is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vasudevan's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 67 Advanced Conditions
    View All 141 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile